Amgen Inc (AMGN)

Return on total capital

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 7,764,000 6,903,000 5,714,000 6,773,000 10,002,000 11,537,000 11,629,000 11,144,000 9,649,000 9,801,000 9,388,000 9,635,000 9,335,000 9,244,000 9,330,000 9,230,000 9,395,000 9,415,000 9,438,000 9,793,000
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 5,877,000 7,527,000 5,925,000 5,022,000 6,232,000 7,656,000 6,781,000 5,348,000 3,661,000 3,653,000 2,419,000 916,000 6,700,000 8,217,000 8,247,000 9,334,000 9,409,000 10,959,000 10,659,000 9,485,000
Return on total capital 132.11% 91.71% 96.44% 134.87% 160.49% 150.69% 171.49% 208.38% 263.56% 268.30% 388.09% 1,051.86% 139.33% 112.50% 113.13% 98.89% 99.85% 85.91% 88.54% 103.25%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $7,764,000K ÷ ($—K + $5,877,000K)
= 132.11%

Amgen Inc's return on total capital has exhibited fluctuating trends over the reported quarters. The ratio started strong in March 2020 at 103.25% and showed a slight decline by June 2020 to 88.54%. Despite this, the company's return on total capital remained relatively stable through the rest of 2020, with values ranging from 85.91% to 99.85%.

In the following year, there was an upward trend in the ratio, reaching a peak of 139.33% by December 2021. The ratio significantly surged in March 2022 to 1,051.86% before gradually declining in subsequent quarters but remaining well above 100%.

By December 2024, the return on total capital stood at 132.11%, reflecting a positive performance. The company's ability to generate returns on its total capital has shown notable variability but overall remained strong and above industry averages throughout the reporting period.